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Introduction
Advanced or mRCC has historically had a poor prognosis, with a median survival rate of approximately 13 months between 1996 and 2003. 1 However, 5-year survival has increased over time from 7.3% (1992-1995) to 12.3% (2003-2009 ). 2 In Japan, the National Cancer Institute estimated that 23 082 Japanese people were diagnosed with renal/urothelial cancer in 2011 (excluding bladder cancer), with 8793 deaths resulting from this disease in 2014. such as interferon, could not been shown in most of the clinical trials of first-line treatment, and regulatory approval had been based on PFS benefit. 6 OS in patients with mRCC has doubled over the past decade, largely due to the availability and sequencing of these agents. 6 There is still a significant unmet medical need, especially for patients who have failed to respond to prior anti-angiogenic therapy.
Information on real-world treatment patterns and outcomes is informative for clinical practice in this setting, but the information is limited. [7] [8] [9] [10] [11] By studying treatment patterns and outcomes in patients with mRCC, to understand unmet needs, clinical outcomes and the burden of disease after progression from first-line therapy might be understood. Uniformly collecting data across countries should allow for the assessment of regional variations in treatment patterns and the associated impact on outcomes.
The aim of the present study focused on the era before the introduction of the immuno-oncology agent, nivolumab, which was to clarify real-world treatment patterns, patient responses and outcomes from 2012 to August 2016, when the first-and second-line TKI sequences of treatment were established using sunitinib and axitinib.
Methods

Study design
This was a multicenter, retrospective, medical chart review study that was implemented in seven academic hospitals in Japan using an electronic data capture system based on patient medical records.
Patients
The present study was approved by the internal review boards of the participating institutions. Participating physicians were required to screen patients with a diagnosis of mRCC who underwent treatment with the following inclusion criteria: (i) aged ≥20 years at the time of the initial diagnosis of mRCC; (ii) alive or deceased as of the date of data collection; and (iii) diagnosed with mRCC between 1 January 2012 and 31 August 2015. The medical records of each patient were investigated through to 31 August 2016. Patients who had been treated with immune checkpoint inhibitors at any point within the period and those who had primary cancer, except RCC, were excluded.
End-points and assessments
Data on the date of mRCC diagnosis, sex, age, eGFR, ECOG PS, risk category based on MSKCC score, tumor tissue type, presence or absence of metastatic site and the number of metastases at each site were collected as patient characteristics. The data were collected for prior nephrectomy without distinguishing between radical and cytoreductive nephrectomies. Data on the first-line and subsequent drugs administered were recorded, including the initiation and discontinuation dates, grade ≥3 AEs, and the reason for discontinuation when the drugs were discontinued (disease progression, AE, patient response, patient circumstances or death). The outcomes and survival outcome (alive or deceased) on the last day of the study were recorded. Therapeutic drugs were categorized into three groups: TKI (sunitinib, pazopanib, sorafenib and axitinib), mTORi (everolimus and temsirolimus), and cytokine and others ("cytokine" hereinafter: IL-2, IFN-a and others).
Three end-points were defined. The proportions of patients who followed each pattern, as well as reasons for the discontinuation of each treatment were assessed. OS was defined in two ways as time from the date of mRCC diagnosis for survival estimation of all patients, and analysis of impact of patient characteristics on OS and time from initiation of first-line therapy to death for the evaluation of systemic treatment. Grade ≥3 AEs reported with TKI, mTORi or cytokine were counted by both the treatment category and the drug.
Statistical analysis
Descriptive statistics were used to show the patient characteristics, treatment pattern, treatment duration, reason for discontinuation and AEs. Summary statistics for continuous outcomes included the median, interquartile range, range and mean AE SD. Summary statistics for categorical and conventional outcomes included the frequency and percentage.
The Kaplan-Meier method was used to compute the median OS and 95% CI. For the analysis of the impact of patient characteristics on OS, the Cox proportional hazards model was used to calculate the univariate HRs and their 95% CIs, and the HRs were computed in multivariate analysis using the significant variables. We used SAS (version 9.4; SAS Institute, Cary, NC, USA) for all statistical analyses.
Results
Patient disposition and baseline characteristics
A total of 297 patients were enrolled. Of these, 20 patients were excluded because of their ineligibility. Data from the medical records of the 277 patients were collected after review by the investigators and were included in the analyses. Table 1 shows the patient baseline characteristics. A total of 82% of patients underwent nephrectomy, and 65% of patients had poor renal function (eGFR <60). In 15.5% of patients, systemic treatment was started ≥5 years after the cancer surgery. By the end-of-study date (31 August 2016), 139 patients were alive, 94 had died and 44 had been censored.
Treatment pattern
Of the 277 eligible patients, 11 did not receive any drug therapy and 266 (96%) received drug therapies as first-up to seventh-line therapy. Figure 1 shows the treatment patterns up to third-line therapy. A total of 192 patients received TKI as first-line therapy (TKI-1st patients; Fig. 1a ), of which 125 (65.0%) initiated second-line therapy, including 100 (52.0%) switching to another TKI (TKI-TKI). The most frequently selected first-line TKI was sunitinib (72.9%), and for secondline was axitinib (89.0%). Of the TKI-TKI patients, 24 patients (24.0%) received an mTORi as third-line therapy, and 20 (20.0%) received a TKI. A total of 24 patients (12.5%) received first-line TKI and second-line mTORi (TKImTORi), whereas 38 (14.3%) received first-line mTORi (mTORi-1st patients; Fig. 1b ), of whom 20 (52.6%) received TKI as second-line therapy. A total of 36 patients (13.5%) selected cytokine or another type of drug as first-line therapy (Fig. 1c) ; 24 of these received second-line TKI. Of the 77 patients who received third-line therapy, the most common pattern was TKI-TKI-mTORi (24 [33.2%]), followed by TKI-TKI-TKI (20 [26.0%]) and TKI-mTORi-TKI (12 [15.6%] ). The number of treatment lines (mean AE SD) was 2.0 AE 1.2 for 36 months, and 2.1 AE 1.3 over the entire period.
Patient characteristic by first-line therapy
First-line therapy was selected according to baseline patient characteristic (Table 1) . TKI was widely used. Patients who relapsed after ≥5 years from surgery, TKI was mostly used. mTORi was frequently used for patients in a poor condition (PS2-4, MSKCC poor risk), and it was also administered for non-clear cell type RCC. Cytokine therapy was administered to young patients and those with a good PS, and the proportion with a BMI >25 was high. Most of the metastatic sites were the lung, and most of them had only one metastasis.
Efficacy
The median OS from mRCC diagnosis for all patients (n = 277) was not reached (95% CI 39.3-not estimable), with a median follow-up period of 22.9 months. Figure 2a shows the OS for patients treated with drugs defined as the time from initiation of first-line therapy. With a median follow-up period of 19.8 months, more than half of the patients (52.3%) survived at 48 months, and the median OS was also not reached (95% CI 36.3-not estimable).
OS by first-line treatment category is shown in Figure 2b . The median OS for cytokine-or TKI-1st patients was not reached, and that for mTORi-1st patients was 12.5 months. The difference was mirrored by differences in patient characteristics in the first-line treatment groups, as summarized above.
Among TKI-1st patients receiving first-line TKI for ≥6 months (longer-TKI-1st patients, n = 89), the prognosis was more favorable than in patients (n = 103) who discontinued first-line TKI within <6 months of treatment initiation (Fig. 2c) ; the adjusted HR was 0.320. Compared with the longer-TKI-1st patients (Table S1) , there were more patients in the early discontinued-TKI-1st patients with a poor MSKCC risk (25.0% vs 3.4%) and more with a BMI <25 kg/m 2 (82.1% vs 65.3%). Prognosis was similar after the initiation of second-line therapy between the TKI-TKI (n = 100) and TKI-mTORi patients (n = 24; Fig. 2d) .
Axitinib was the most frequently used second-line therapy, and the ORR was 14.4%. The ORR of axitinib varied by first-line therapy: TKI 13.5%, mTORi 22.2% and cytokine 11.1%. The prognosis was better for patients who continued axitinib as second-line therapy for ≥1 year, compared with those who discontinued it within a year (Fig. S1) .
Analysis of the impact of patient characteristics on OS
The univariate and multivariate HRs regarding the impact of patient characteristics on OS are shown in Figure 3 
Safety and reason for discontinuation
Aggregate results on grade ≥3 AEs are shown by drug category in Table 2 . Frequencies of other AEs are similar between each TKI treatment ( Table 2) . Within mTORirelated AEs, the frequencies of AEs were similar between everolimus and temsirolimus (Table 3 ). In addition, no AEs were observed in the IL-2 treatment line. The frequency of AEs was lower in cytokines than TKI or mTORi ( Table 4 ).
The most common reasons for discontinuation of therapeutic line were disease progression in TKI (49% of all reasons that led to TKI discontinuation), mTORi (44%) and cytokine (64%). The occurrence of AEs was also one of the dominant reasons for discontinuation. It accounted for 42% and 34% of the reasons for termination of TKI and mTORi, respectively, which were higher than for termination of cytokine (16.7%).
Discussion
Recent advances in systemic treatment options for mRCC have greatly improved the patient's outcome in Japan. Shinohara et al. 11 and Naito et al. 12 reported that the median OS for patients with mRCC treated in the cytokine era was 22 and 21.4 months, respectively. Shinohara et al. showed improved outcome, a median OS of 27.2 months, in those patients who started treatment between 2008 and 2010, which might be considered as the beginning of the era of moleculartargeted therapy. 13 The present study showed the treatment pattern and prognosis in patients with a diagnosis of mRCC between 2012 and 2015 who underwent systemic treatments in the era of molecular-targeted therapy. The predominant sequence was TKI-TKI (n = 100, 58.8% of 170 patients who received second-line therapy), followed by TKI-mTORi (n = 24, 14.1%) and mTORi-TKI (n = 20, 11.8%). Recent real-world chart review studies carried out in the USA 9 and Australia 10 showed a different treatment sequence of first-line TKI followed by mTORi (everolimus or temsirolimus) as the predominant second-line therapy. The present study could be considered to represent the features of systemic mRCC treatment in Japan, as well as the prognosis from TKI treatment. The estimated median OS was longer in cytokine-1st, and shorter in mTORi-1st, than in TKI-1st, as shown in Figure 2b . The results indicate that physicians were selecting the optimal treatment for each patient with careful consideration, resulting in the difference in the characteristics between each treatment category. Immunotherapy with cytokine has contributed to an improved prognosis of RCC patients since the Data shown are n (%) unless otherwise stated. 1990s, 14 so newly introduced immuno-oncology is expected to benefit their outcomes.
The median OS of TKI-1st patients had not been reached at 48 months, which was superior to the results of pivotal trials of sunitinib and axitinib, [15] [16] [17] and reports from other countries. 9, 10 Compared with other retrospective studies carried out before 2013, TKI-1st patients in the present study should have better prognoses due to the established treatment strategy with TKIs as first-and second-line therapy. 7, 8 TKIs were well tolerated and showed preferable outcomes in the present study. Among TKI-1st patients, 140 were treated with sunitinib as first-line therapy, with a median treatment duration of 22.4 months. Of these patients, the median OS was not reached, and the median PFS was 12.8 months with an ORR of 17.1%. Axitinib was selected as second-line therapy in the majority of both post-TKI (n = 89) and post-cytokine (n = 18) patients, with a median treatment duration of 13.7 and 25.5 months, respectively. The estimated median OS in these patients was 43.2 months and not reached, respectively, and the median PFS was 9.3 and 37.1 months, respectively.
A significant percentage of patients was found to have limited benefit from TKI treatment. Among 192 TKI-1st patients, 103 (54% of the TKI-1st patients or 37% of all patients) were early discontinued-TKI-1st patients, of which 93 (90.3%) discontinued due to AEs or disease progression. The OS was poorer than longer-TKI-1st patients (Fig. 2c) . Compared with longer-TKI-1st patients, early discontinued-TKI-1st patients had different characteristics, such as high percentage of ECOG PS 1-3 (31.1% vs 17.9%, P = 0.027), high percentage of poor MSKCC risk (25% vs 3.4%, P < 0.001) and low BMI (<25, 82.1% vs 65.3%; ≥25, 7.9% vs 34.7%, P = 0.019), all of which might make long-term treatment more difficult and require a more careful choice of treatment. It is reported that visceral fat accumulation or high BMI correlates with improved OS or PFS. 18, 19 Low BMI, a possible predictor of negative outcome, was one of the factors that inhibited disease conditions from stabilizing at the initial treatment.
Among 125 patients who were treated with axitinib as second-line therapy, 88 discontinued treatments within a year and showed poor survival (Fig. S1 ). Nivolumab, a recently introduced immuno-oncology agent, showed survival benefit in the Japanese subgroup analysis of the phase III trial (Checkmate 025), for which median OS for pre-treated mRCC patients was not reached (median follow-up period 33.2 months). 20 It would therefore be suggested that nivolumab could fill the unmet need of TKI-TKI sequence treatment by achieving an OS benefit with better quality of life, and could be a beneficial treatment option for second-or later-line treatment.
The factors that impacted on OS were similar to those previously reported, as shown in Figure 3 . As mentioned earlier, BMI was lower in the early discontinued-TKI-1st patients than the longer TKI-1st patients; however, the HR for OS in overall patients did not reach a statistically significant level (HR 0.61, P = 0.0794). Although other studies reported that the duration from histopathological diagnosis to the initiation of TKI is a key predictor of survival in patients who received first-line TKI, 21 in the present study, the HR for the impact on OS of the duration from diagnosis of metastasis to the initiation of systemic treatments was not significant (univariate HR 0.46, P = 0.0794). Further investigation into the impact of these potential predictors on treatment strategy is expected in the immuno-oncology era.
The present study had some limitations. First, it used a retrospective design and might contain bias. Some records of the information on reasons for medication change or prognosis were missing and might not have been correctly reported. These could have led to an underestimation of AEs or overestimation of the survival rate. Second, a central review was not carried out, and each investigator was responsible for evaluating the pathology and treatment response, which might have led to biases in data or assessment in each hospital. Third, the minimum follow-up period was only 1 year in this study setting. Also, we found that a significant proportion of patients (75/277, 27%) were censored within <2 years. Evaluation of prolonged treatment patterns or long-term prognosis might be improved by a longer observation period.
In conclusion, the present study showed the treatment pattern and prognosis of patients diagnosed with mRCC in the era of molecular-targeted therapy. The predominant sequence was TKI-TKI, followed by TKI-mTORi and mTORi-TKI. The median OS was not reached at 48 months. Along with an OS benefit with TKI treatment, we suggest patients who received first-line TKI for <6 months had poor prognoses, suggesting the need for better treatment options. and personal fees from Pfizer and Novartis; and personal fees from Bayer and Shionogi outside the submitted work. Dr Shinohara has received the grants from Ono Pharmaceutical and Pfizer, and the speaker honoraria from Ono Pharmaceutical, Pfizer, Novartis and GSK. Dr Tomita reports grants from
